Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Shares Outstanding (Diluted Average) (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Shares Outstanding (Diluted Average) data on record, last reported at $129.9 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 4.8% year-over-year to $129.9 million; the TTM value through Dec 2025 reached $129.9 million, up 4.8%, while the annual FY2025 figure was $129.9 million, 4.8% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $129.9 million in Q4 2025 per APLS's latest filing, up from $126.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $129.9 million in Q4 2025 and bottomed at $79938.0 in Q2 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $79.1 million, with a median of $117.6 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): skyrocketed 114893.12% in 2023, then increased 1.71% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $84.4 million in 2021, then grew by 25.7% to $106.1 million in 2022, then rose by 11.84% to $118.7 million in 2023, then increased by 4.4% to $123.9 million in 2024, then grew by 4.8% to $129.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $129.9 million in Q4 2025, $126.0 million in Q2 2025, and $125.5 million in Q1 2025.